Front > HEALTHCARE

HEALTHCARE

Biomed (Illustration: Shutterstock) Israeli co Enlivex Therapeutics raises $8m

The financing led by Korea Investment Partners will fund Phase III clinical trials of the Jerusalem company's lead compound for the prevention of Graft Vs Host Disease (GVHD).

Teva Teva teams with Nuvelution on Tourette syndrome drug

The two companies will develop AUSTEDO (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome in pediatric patients in the US.

Cannabis Agriculture Ministry to recognize cannabis as farming sector

Cannabis growers for medical use will receive support, grants, water quotas, and training.

Teva Photo: Tamar Matsafi Teva in talks with Azrieli to rent new Petah Tikva HQ

Azrieli yesterday bought land in Petah Tikva from Amos Luzon and Tidhar.

Gal Cohen MediWound raises $22m in Nasdaq offering

The company's wound treatment product has successfully passed Phase II trials.

Augmedics  photo: PR Israeli surgical visualization co Augmedics raises $8.3m

The round was led by Swiss fund AO Invest.

Essence Group  photo: PR Smart home means safe home for seniors

Israeli company Essence develops products that enable people to keep living at home in old age.

bio, biotech, lab, microscope, medicine Israel Innovation Authority eyes second biotech incubator

The success of FutuRX in Rehovot has led the Innovation Authority to plan an incubator in northern Israel as well.

Yitzhak Peterburg Photo: PR Teva sells remaining women's health assets for $1.38b

Together with the sale of Paragard, Teva will realize $2.48 billion for repayment of loan debt.

CollPlant tobacco greenhouse, photo:PR Collplant receives first order for biological ink

The ink is designed for 3D printing of organs and tissues for healing wounds.

Teva  photo: Reuters Teva using less water, producing less garbage

Teva's 2016 social impact report shows women doing well in lower management but under-represented in the most senior posts.

Stella Handler  photo: PR/Yanai Yehiel Bezeq to support 8200 Social Program

Bezeq will give each startup in the social technology accelerator communications services worth NIS 1,000 a month.

Kamada Brosh fund acquires 6.2% Kamada stake

Kamada's share price has plunged 40% in the past three months, following failure in a drug trial.

Ra'anana campus Photo: Alon Ron Amdocs buys Ra'anana site from Teva

Amdocs paid NIS 200 million for the land on which Teva had planned to build its headquarters.

Lab Technician.  Photo: Reuters Entera Bio raising $10m at $94m valuation

Entera is developing a drug for the treatment of osteoporosis.

Prof Michal Schwartz photo: Rami Zarnegar "Lady Globes" Woman of the Year: Prof. Michal Schwartz

The Weizmann Institute researcher's groundbreaking research on Alzheimer's Disease is leading to new treatment for it.

Kare Schultz photo: PR Analysts welcome Teva CEO move

One investment bank has upgraded Teva to "Buy" following the appointment of Kåre Schultz.

Benny Landa Photo: Eyal Yizhar Benny Landa: Teva board still needs shaking up

Activist Teva investor Landa hopes new CEO Kare Schultz will wean the company off generics.

Yitzhak Peterburg Photo: Eyal Yizhar Teva sells Paragard contraceptive to CooperSurgical for $1.1b

Teva interim CEO Yitzhak Peterburg: This is an important step towards completing the divestments we have promised our stakeholders.

Omar Ishrak Photo: Reuters Medtronic to set up Israeli R&D centers

The medical equipment firm is opening development centers in Jerusalem and Yokneam in cooperation with the Israel Innovation Authority.

Sol Barer  photo: Teva website Teva chairman Barer: Schultz is ideal for the job

Dr. Sol Barer spoke to "Globes" about what Teva CEO-designate Kåre Schultz brings to the company.

K?re Schultz photo: PR Teva appoints Kare Schultz CEO

Schultz is currently CEO of H. Lundbeck. He will be based at Teva's Petah Tikva headquarters. Teva's share price is up sharply.

Nasdaq Photo: Reuters "Healthcare cos should consider delisting from TASE"

Orbimed fund senior managing partner Nissim Darvish: TASE listing detracts from a company's value.

Calma Photo: HIT Israel's Calma uses virtual reality to treat autism

The system was developed by students at the Holon Institute of Technology.

Avi Tiomkin  photo: Einat Levron Teva's collapse could happen to Israeli economy

Israel is putting too many eggs in the startup basket, warns Avi Tiomkin.

Dr. Oron Yacoby-Zeevi Photo: PR How we achieved Israel's biggest-ever pharma exit

CSO Dr. Oron Yacoby-Zeevi tells about the day Neuroderm almost closed down, and how Israeli venture capital funds missed the opportunity to invest.

Teva  photo: PR Nobody would buy Teva because of its debt

Pharmaceutical rivals will to try to exploit Teva's weakness and buy activities from it that are profitable, writes Omri Cohen.

Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017